Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal)
Technology appraisal
Reference number: TA1068
Published:
For information, tislelizumab has now been acquired by the company Beigene. NICE are liaising with the company regarding appropriate timelines for this appraisal and further information will be available in due course.